TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02448784

Intervention type: DRUG
Intervention: Donepezil Hydrochloride
Description: Initial dose for oral use is 3 mg once daily. The dose is increased to 5 mg after 1-2 weeks. Following at least 4 weeks of dosing at 5 mg, the dose is increased to 10 mg. The dose may be decreased to 5 mg depending on the symptoms of the participant.
Study: NCT03146520

Intervention type: DEVICE
Intervention: EarlyTect Colon Cancer
Description: SDC2 methylation assay by qPCR using EarlyTect Colon Cancer kit

Intervention type: DEVICE
Intervention: EarlyTect Colon Cancer
Description: SDC2 methylation assay by qPCR using EarlyTect Colon Cancer kit

Intervention type: DEVICE
Intervention: EarlyTect Colon Cancer
Description: SDC2 methylation assay by qPCR using EarlyTect Colon Cancer kit

Intervention type: DEVICE
Intervention: EarlyTect Colon Cancer
Description: SDC2 methylation assay by qPCR using EarlyTect Colon Cancer kit
Study: NCT04132609

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive bias modification
Description: : In CBM, the task presentation and timing is the same as attentional bias, except the probe always replaces the neutral word. It ensures that: 1) the duration of CBM and control training should not differ; 2) CBM and control participants receive equal practice on the motoric aspects of the task; and 3) CBM and control participants are exposed to the same word cues. Based on previous data, duration of CBM and control trainings will be about 10 minutes.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard attentional bias
Description: the standard attentional bias task, a drug or pain-related word is presented next to a neutral word for 500ms. Subsequently, a probe (i.e., a q or p) replaces the drug/pain word or the neutral word at an equal rate. The participant's task is to indicate the location of the probe as quickly as possible by pressing q or p. Attentional bias is calculated from the difference in reaction times (i.e., neutral cue minus drug/pain cue) to indicate the location of the probe, with higher values indicating greater attentional bias. For all tasks, opioid and pain words will be presented in separate blocks in counterbalanced order. Neutral words paired with opioid or pain words will be matched for length and frequency of use in the English language.
Study: NCT01732367

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine plus adefovir
Description: Lamivudine 100mg QD for 96 weeks + Adefovir 10mg QD for 96 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Description: Tenofovir 300mg QD for 96 weeks
Study: NCT03820661

Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasound
Description: High resolution ultrasound pre-operatively and intra-operatively
Study: NCT00506415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine 10 cm^2
Description: 10 cm\^2 transdermal patch.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine 10 cm^2
Description: 10 cm\^2 transdermal patch.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine 15 cm^2
Description: 15 cm\^2 transdermal patch.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to 15 cm^2 patch
Description: Placebo of rivastigmine transdermal patch 15 cm\^2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to 10 cm^2 patch
Description: Placebo of rivastigmine transdermal patch 10 cm\^2.
Study: NCT02298777

Intervention type: PROCEDURE
Intervention: - Skin biopsy - Urine sample - Blood sample

Intervention type: PROCEDURE
Intervention: - Skin biopsy - Urine sample - Blood sample

Intervention type: PROCEDURE
Intervention: - Skin biopsy - Urine sample - Blood sample

Intervention type: PROCEDURE
Intervention: - Skin biopsy - Urine sample - Blood sample

Intervention type: PROCEDURE
Intervention: - Skin biopsy - Urine sample - Blood sample
Study: NCT03286556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autoantibody Reductive Therapy
Description: TPE x 9, rituximab x 2, IVIG x 4. See arm/group descriptions for additional details.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Antibiotics and steroids
Study: NCT02164539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF
Description: Fluticasone furoate is available as fluticasone furoate inhalation powder (100 mcg per blister), combination of fluticasone furoate/umeclidinium bromide inhalation powder (fluticasone furoate: 100 mcg per blister, umeclidinium bromide: 15.6, 62.5, 125, or 250 mcg per blister) and combination of fluticasone furoate/vilanterol inhalation powder (fluticasone furoate: 100 mcg per blister, vilanterol: 25 mcg per blister)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF
Description: Fluticasone furoate is available as fluticasone furoate inhalation powder (100 mcg per blister), combination of fluticasone furoate/umeclidinium bromide inhalation powder (fluticasone furoate: 100 mcg per blister, umeclidinium bromide: 15.6, 62.5, 125, or 250 mcg per blister) and combination of fluticasone furoate/vilanterol inhalation powder (fluticasone furoate: 100 mcg per blister, vilanterol: 25 mcg per blister)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UMEC
Description: Umeclidinium bromide is available as combination of fluticasone furoate/umeclidinium bromide inhalation powder (fluticasone furoate: 100 mcg per blister, umeclidinium bromide: 15.6, 62.5, 125, or 250 mcg per blister)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UMEC
Description: Umeclidinium bromide is available as combination of fluticasone furoate/umeclidinium bromide inhalation powder (fluticasone furoate: 100 mcg per blister, umeclidinium bromide: 15.6, 62.5, 125, or 250 mcg per blister)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UMEC
Description: Umeclidinium bromide is available as combination of fluticasone furoate/umeclidinium bromide inhalation powder (fluticasone furoate: 100 mcg per blister, umeclidinium bromide: 15.6, 62.5, 125, or 250 mcg per blister)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI
Description: Vilanterol is available as vilanterol inhalation powder (25 mcg per blister) and combination of fluticasone furoate/vilanterol inhalation powder (fluticasone furoate: 100 mcg per blister, vilanterol: 25 mcg per blister)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI
Description: Vilanterol is available as vilanterol inhalation powder (25 mcg per blister) and combination of fluticasone furoate/vilanterol inhalation powder (fluticasone furoate: 100 mcg per blister, vilanterol: 25 mcg per blister)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI
Description: Vilanterol is available as vilanterol inhalation powder (25 mcg per blister) and combination of fluticasone furoate/vilanterol inhalation powder (fluticasone furoate: 100 mcg per blister, vilanterol: 25 mcg per blister)
Study: NCT00802529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 2 transtympanic injections at interval of two weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gentamicin
Description: 2 transtympanic injections at an interval of two weeks. If there is significant hearing loss before second injection, it will be replaced by normal saline in double blinded fashion.
Study: NCT02440932

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Phenylketonuria-type diet
Description: Breakfast, lunch and open buffet dinner

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phenylketonuria-type diet
Description: Breakfast, lunch and open buffet dinner

Intervention type: OTHER
Group type: OTHER
Intervention: Normal (control) diet
Description: Breakfast, lunch and open buffet dinner

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal (control) diet
Description: Breakfast, lunch and open buffet dinner
Study: NCT01800669

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHICA MLP Module
Description: The MLP module screens families for medical-legal issues, alerts the physician to there presences and provides guidance and referral materials to help the physician resolve the issues.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CHICA without the MLP module
Description: Clinics in the control group will have the CHICA system, but without the MLP module. It will screen for medical-legal issues but will not provide additional guidance and referrals to help resolve them.
Study: NCT03031431

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Electric Infant Warmer
Description: Electric warmers are the standard of care in developed countries, but are extremely costly, complicated with risk of causing both hypo and hyperthermia with misuse, and often not feasible in settings without stable electricity. Through a multi-institutional collaboration, the investigators have developed an electricity-free infant warmer.
Study: NCT01698762

Intervention type: OTHER
Intervention: Multimedia Patient Decision Aids (MM-PtDAs)
Description: Patient group will watch a DVD of information about their disease type.

Intervention type: OTHER
Intervention: Multimedia Patient Decision Aids (MM-PtDAs)
Description: Patient group will watch a DVD of information about their disease type.

Intervention type: OTHER
Intervention: Multimedia Patient Decision Aids (MM-PtDAs)
Description: Patient group will watch a DVD of information about their disease type.

Intervention type: OTHER
Intervention: Comparative Effectiveness Research Summary Guide (CERSG)
Description: Patient group to read a booklet about their disease type.

Intervention type: OTHER
Intervention: Comparative Effectiveness Research Summary Guide (CERSG)
Description: Patient group to read a booklet about their disease type.

Intervention type: OTHER
Intervention: Comparative Effectiveness Research Summary Guide (CERSG)
Description: Patient group to read a booklet about their disease type.

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Questionnaires completed at baseline, 3, and at 6 months.

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Questionnaires completed at baseline, 3, and at 6 months.

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Questionnaires completed at baseline, 3, and at 6 months.
Study: NCT02063386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1722
Description: Single oral dose 15 mg of \[14C\]AZD1722
Study: NCT00448682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Floxuridine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Study: NCT03109522

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: axillary reverse mapping (ARM)
Description: ARM/SLNB: patient will be injected with technetium-99 radiolabelled colloid (Tc-99) into the subareolar area of breast, then 1-2 mls of blue dye (patent blue dye) injected subcutaneously into the medial ipsilateral arm, just proximal to the medial epicondyle of the elbow, at the start of the surgical procedure. the SLN(s) will be identified (hot node) and removed, and any blue lymph nodes and lymphatics will be preserved intact, and only removed or disrupted if there is 'crossover (i.e. the blue node is also the SLN) or if clinically suspicious for metastatic disease. ARM/ALND: 1-2 mls of blue dye will be injected subcutaneously into the medial ipsilateral arm at the start of the surgical procedure. Surgeons will perform a standard level I and II axillary dissection and any blue lymph nodes or lymphatics will be preserved intact, and only removed or disrupted if blue nodes are suspicious for metastatic disease.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard axillary surgery (SLNB or ALND)
Description: The control group will have standard SLNB or ALND surgery without identifying or sparing upper-limb lymphatics and nodes (blue dye is not injected).
Study: NCT04632693

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CAF with SCTG and Vitamin C injection
Description: Injection of vitamin C after CAF with SCTG aiming to increase gingival thickness in patients with RT1 gingival recession.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CAF with SCTG alone
Description: Coronally advanced flap with subepithelial connective tissue graft.
Study: NCT01143272

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saccharomyces boulardii
Description: Units: 500 mg per day Route of administration : Oral Use Hard-Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02465307

Intervention type: BEHAVIORAL
Intervention: Confusion Assessment Method
Description: Confusion Assessment Method (CAM) score

Intervention type: BEHAVIORAL
Intervention: Confusion Assessment Method
Description: Confusion Assessment Method (CAM) score

Intervention type: DEVICE
Intervention: Accelerometer
Description: 3 accelerometers (placed on upper arm, wrist and ankle) and 1 placed on wall as ambient light sensor

Intervention type: DEVICE
Intervention: Accelerometer
Description: 3 accelerometers (placed on upper arm, wrist and ankle) and 1 placed on wall as ambient light sensor

Intervention type: DEVICE
Intervention: Accelerometer
Description: 3 accelerometers (placed on upper arm, wrist and ankle) and 1 placed on wall as ambient light sensor

Intervention type: DEVICE
Intervention: Commercially available camera
Description: As part of facial recognition video system

Intervention type: DEVICE
Intervention: Commercially available camera
Description: As part of facial recognition video system

Intervention type: DEVICE
Intervention: Internet Pod (iPod)
Description: Monitors noise levels in the room

Intervention type: DEVICE
Intervention: Internet Pod (iPod)
Description: Monitors noise levels in the room

Intervention type: DEVICE
Intervention: Internet Pod (iPod)
Description: Monitors noise levels in the room

Intervention type: DIAGNOSTIC_TEST
Intervention: Cortisol Swab
Description: Cortisol level collected through self administered salivary swab
Study: NCT00972153

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air Barrier System Device
Description: Device is deployed adjacent to the surgery site and activated so that the filtered air emits over the surgery site.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Air Barrier System device
Description: Device is deployed to the surgery site, but the airflow is not activated. This intervention is used to determine any effects that the presence of the device alone may have.
Study: NCT02837367

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Administration of supplements containing methyl-donors
Description: Administration of supplements containing methyl-donors: betaine, 5-MTHF (L-5-methyltetrahydrofolate), Vitamin B12, choline bitartrate, ALA (alfa-linolenic acid), EPA (eicosapentaenoic acid), DHA(docosahexaenoic acid)
Study: NCT03016871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study: NCT02837367

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Administration of supplements containing methyl-donors
Description: Administration of supplements containing methyl-donors: betaine, 5-MTHF (L-5-methyltetrahydrofolate), Vitamin B12, choline bitartrate, ALA (alfa-linolenic acid), EPA (eicosapentaenoic acid), DHA(docosahexaenoic acid)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Administration of supplements containing methyl-donors
Description: Administration of supplements containing methyl-donors: betaine, 5-MTHF (L-5-methyltetrahydrofolate), Vitamin B12, choline bitartrate, ALA (alfa-linolenic acid), EPA (eicosapentaenoic acid), DHA(docosahexaenoic acid)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Administration of supplements containing methyl-donors
Description: Administration of supplements containing methyl-donors: betaine, 5-MTHF (L-5-methyltetrahydrofolate), Vitamin B12, choline bitartrate, ALA (alfa-linolenic acid), EPA (eicosapentaenoic acid), DHA(docosahexaenoic acid)
Study: NCT01440647

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extubation to NIPPV
Description: After extubation infants were placed on NIPPV as soon as all the extubation criteria were met

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extubation to CPAP
Description: After extubation infants were placed on CPAP
Study: NCT00606801

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Galantamine
Description: Galantamine 8 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: sugar pill
Study: NCT01203319

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 60mcg/1.0ml recombinant hepatitis B vaccine
Description: to receive 60mcg/1.0ml recombinant HBV vaccines on day 0, 30 and 60

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30mcg/1.0ml recombinant hepatitis B vaccine
Description: to receive 30mcg/1.0ml recombinant hepatitis B vaccines on day 0, 30 and 60.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 10mcg/1.0ml recombinant hepatitis B vaccine
Description: to receive 10mcg/1.0ml recombinant hepatitis B vaccines on day 0, 30 and 60
Study: NCT01159119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EUR-1066-A
Description: Eur-1066 capsules taken daily for 28 days either during treatment period 1 or treatment period 3.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zenpep
Description: Capsules taken for daily for 28 days during treatment period 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EUR-1066-B
Description: Eur-1066 capsules taken daily for 28 days either during treatment period 1 or treatment period 3.
Study: NCT04537819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imupret in addition to local NAID
Description: Additional prescription of Imupret oral drops to conventional therapy with local NAID (Benzydamine hydrochloridy), elimination of irritating factors in the diet and acetaminophen (if necessary)

Intervention type: DRUG
Group type: OTHER
Intervention: Local NAID (Benzydamin)
Description: (Benzydamine hydrochloridy) and acetaminophen (if necessary), elimination of irritating factors in the diet
Study: NCT01000545

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulodexide
Description: SLX 500 LRU, SLX 1000 LRU, SLX 2000 LRU per day to be taken orally for 12 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulodexide
Description: SLX 500 LRU, SLX 1000 LRU, SLX 2000 LRU per day to be taken orally for 12 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulodexide
Description: SLX 500 LRU, SLX 1000 LRU, SLX 2000 LRU per day to be taken orally for 12 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo capsules
Description: 8 soft-gel capsules per day to be taken orally for 12 months
Study: NCT03079674

Intervention type: OTHER
Intervention: observational only- no intervention
Description: observational only- no intervention
Study: NCT03780569

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF-200A
Description: Patients receive continuous TTFields treatment using the NovoTTF-200A device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the scalp. The treatment enables the patient to maintain regular daily routine.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 60Gy given in 30 2Gy fractions concomitant to temozolomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide(TMZ) will be administered at 75 mg/m\^2 concomitant to radiotherapy(RT) and NovoTTF-200A.~Maintenance treatment is to begin about 4 weeks after the end of TMZ/RT/NovoTTF-200A. TMZ is administered at the conventional dosing regimen for 5 days, every 28 days (i.e. 5 days of therapy, 23 days of rest). Cycle 1 is to be given at a dose of 150 mg/m\^2 p.o. daily x 5 days, dose to be escalated to 200 mg/m\^2 in the absence of toxicity.
Study: NCT03016871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT04147611

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BAHA
Description: Participant's pediatric bone conduction hearing device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BAHA
Description: Participant's pediatric bone conduction hearing device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wireless Audio Streaming Accessory
Description: Cochlear Corporation's Mini Microphone 2+ Wireless Audio Streaming Accessory is an accessory used to transmit speech and sound. It consists of a microphone and a transmitter that transfers the signal to a receiver that's connected to a hearing device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wireless Audio Streaming Accessory
Description: Cochlear Corporation's Mini Microphone 2+ Wireless Audio Streaming Accessory is an accessory used to transmit speech and sound. It consists of a microphone and a transmitter that transfers the signal to a receiver that's connected to a hearing device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Digital Adaptive RM System
Description: Sonova's Roger Digital Adaptive RM system is an accessory which can be connected to a compatible hearing aid. It offers an external microphone which streams signals directly to the connected hearing aid.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital Adaptive RM System
Description: Sonova's Roger Digital Adaptive RM system is an accessory which can be connected to a compatible hearing aid. It offers an external microphone which streams signals directly to the connected hearing aid.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hearing Aid
Description: Participant's unilateral hearing aid with contralateral plug.
Study: NCT02026037

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Treatment for Acutely Burned Patients (BTBP)
Description: Brief Treatment for Acutely Burned Patients (BTBP) adapts CBT principles that have been validated with non-burn trauma survivors to the treatment of hospitalized burn patients. BTBP consists of three 1 to 1½ hour sessions per week for two weeks, as well as two sessions for family members or partners/spouses.